Abstract:Funding source: Innovation agency, North-West Coast, NHS England, Vanguard House, Keckwith Lane, WA4 4AB, UK Funding source: Quidel Cardiovascular Inc., San Diego, CA 91121, USA Funding source: Siemens Healthineers Funding source: Menarini Group Funding source: St. George's, University of London Funding source: Liverpool University Hospitals NHS Foundation Trust Funding source: Abbott Diagnostics Research ethics: Signed informed consent has been taken for every recruited participant to MACROS-2. The study has approval of the local Research Ethics Committee and the Health Research Authority. The study was conducted in accordance with the Declaration of Helsinki. Informed consent: Informed consent was obtained from all individuals included in this study, or their legal guardians or wards. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission. AK, YK and JH developed the concept for the manuscript. AL and HF conducted the laboratory imprecision experiments. HF and PC provided guidance on the nuance of imprecision calculation. JH undertook the statistical calculations and wrote the manuscript. AK, PC, ES and GM provided critical appraisal and guidance on the writing of the manuscript. Competing interests: JH states no conflict of interest. PC has received honoraria for lectures with Siemens Healthineers and Abbott Laboratories. He is a consultant to the IFCC Committee on Clinical Applications of Cardiac Bio-Markers (C-CB). ES states no conflict of interest. GM states no conflict of interest. AL states no conflict of interest. HF states no conflict of interest. YK states no conflict of interest. AK has been a speaker or expert speaker for the following companies: Bayer, Daiichi Sankyo, Astra Zeneca, Menarini, St Jude and Abbott Vascular. Research funding: No funding specifically for the production of the manuscript. Following is funding for the MACROS-2 study: Innovation agency, North-West Coast, NHS England, Vanguard House, Keckwith Lane, WA4 4AB. Amount: £47962. Liverpool University Hospital NHS Foundation Trust, Longmoor Lane, Liverpool, L9 7AL. Amount: £60000. Menarini UK, Menarini House, Mercury Park, Wycombe Lane, Wooburn Green, Buckinghamshire, HP10 0HH. Amount: £15000 Abbott Diagnostics, Lake Forest, USA. Amount £50000 (Financial assistance) and £60000 (Sample analysis). Charitable funds of St. Georges Hospital Biochemistry Department, London, UK. Amount: £10000. Quidel Cardiovascular Inc., San Diego, CA 91121, USA. Amount: £140000. Siemens Healthcare Diagnostics Limited, Faraday House, Sir Williams Square, Frimley, Camberley, Surrey GU16 8QD. Amount: £30000. Data availability: The raw data can be obtained on request from the corresponding author. 1. Byrne, RA, Rossello, X, Coughlan, JJ, Barbato, E, Berry, C, Chieffo, A, et al.. 2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 2023;44:3720–826. https://doi.org/10.1093/eurheartj/ehad191. Search in Google Scholar PubMed 2. Pickering, JW, Than, MP, Cullen, L, Aldous, S, Ter Avest, E, Body, R, et al.. Rapid rule-out of acute myocardial infarction with a single high-sensitivity cardiac troponin T measurement below the limit of detection. Ann Intern Med 2017;166:715. https://doi.org/10.7326/m16-2562. Search in Google Scholar 3. van Schrojenstein Lantman, M, Grobben, R, van Herwaarden, AE, van Berkel, M, Schaap, J, Thelen, M. To rule-in, or not to falsely rule-out, that is the question: evaluation of hs-cTnT EQA performance in light of the ESC-2020 guideline. Clin Chem Lab Med 2024;62:1158–66. 10.1515/cclm-2023-1226Search in Google Scholar PubMed 4. Thygesen, K, JosephS, A, AllanS, J, BernardR, C, JeroenJ, B, DavidA, M, et al.. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 2018;72:2231–64. https://doi.org/10.1016/j.jacc.2018.08.1038. Search in Google Scholar PubMed 5. Than, M, Herbert, M, Flaws, D, Cullen, L, Hess, E, Hollander, JE, et al.. What -Abstract Truncated-

Antibody-mediated interferences affecting cardiac troponin assays: recommendations from the IFCC Committee on Clinical Applications of Cardiac Biomarkers

A Rare Case of Falsely Elevated High-Sensitivity Cardiac Troponin T Due to Antibody Interference and a Literature Review

Cardiac troponin measurement at the point of care: educational recommendations on analytical and clinical aspects by the IFCC Committee on Clinical Applications of Cardiac Bio-Markers (IFCC C-CB)

Acute Phase Response and Non-Reproducible Elevated Concentrations with a High-Sensitivity Cardiac Troponin I Assay

Clinical Biochemistry of Serum Troponin

Attention should be paid to false-positive results due to heterophilic antibodies interfering with Abbott high-sensitivity cardiac troponin I assay

The Impact of Antibody Selection on the Detection of Cardiac Troponin I.

High-Sensitivity Cardiac Troponin and the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain

A-014 Fifth Generation Troponin T is Unaffected by Extreme Levels of Lipemia and Icterus

Diagnostic and prognostic value of cardiac troponin I assays in patients admitted with symptoms suggestive of acute coronary syndrome

Why is single sample rule out of non-ST elevation myocardial infarction using high-sensitivity cardiac troponin T safe when analytical imprecision is so high? A joint statistical and clinical demonstration

Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia

Clinical Interpretation of Serum Troponin in the Era of High-Sensitivity Testing

[False positive on macrotroponin]

A-336 Comparative Evaluation of Homogeneous Point-of-Care and Central Laboratory Chemiluminescent Immunoassays for High-Sensitivity Cardiac Troponin I

Troponin in Cardiovascular Disease Prevention: Updates and Future Direction

Evaluation of standardization capability of current cardiac troponin I assays by a correlation study: results of an IFCC pilot project

Rapid identification of falsely elevated serum cardiac troponin I values in a stat laboratory.

Revealing the hidden threat behind detectable cardiac troponin levels in the emergency department

An overview of biochemical markers in acute coronary syndromes

Performance evaluation of a novel high-sensitivity cardiac troponin T assay: analytical and clinical perspectives